The U.S. arteriovenous fistula devices market size was estimated at USD 112.0 Million in 2025 and is projected to reach USD 120.0 million by 2033, growing at a CAGR of 0.9% from 2025 to 2033. The growth is attributed to several factors, including the increasing prevalence rate of End-stage Renal Disease (ESRD) and the resulting rise in the number of patients requiring hemodialysis.
The advanced healthcare infrastructure, a high incidence of diabetes & hypertension, and widespread awareness initiatives in the country are expected to drive the market growth. According to 2023 estimates by the Centers for Disease Control and Prevention (CDC), approximately 14% of adults in the U.S. are affected by chronic kidney disease (CKD). Furthermore, the American Kidney Fund reports that approximately 815,000 Americans are currently living with kidney failure, with nearly 555,000 of them undergoing dialysis, highlighting the widespread need for effective treatment solutions.
Due to the critical shortage of kidney donors, the increasing dependence on dialysis underscores the essential role of AVF devices in managing ESRD. The escalating rate of kidney disease is also driving the demand for more advanced and innovative AVF solutions. AV fistulas are preferred for long-term vascular access because of their durability, lower infection rates, and reduced complication risk compared to other access types. These factors are propelling the growth of AVF devices in the U.S.
Two other types of vascular access for hemodialysis, arteriovenous graft (AVG) and central venous catheter (CVC), are the primary substitutes for an arteriovenous fistula. The choice of access has significant clinical and economic implications, directly impacting market dynamics. While AVFs are considered the gold standard due to lower infection rates and better longevity, their long maturation time and high primary failure rate make substitutes necessary.
This product will be delivered within 2 business days.
The advanced healthcare infrastructure, a high incidence of diabetes & hypertension, and widespread awareness initiatives in the country are expected to drive the market growth. According to 2023 estimates by the Centers for Disease Control and Prevention (CDC), approximately 14% of adults in the U.S. are affected by chronic kidney disease (CKD). Furthermore, the American Kidney Fund reports that approximately 815,000 Americans are currently living with kidney failure, with nearly 555,000 of them undergoing dialysis, highlighting the widespread need for effective treatment solutions.
Due to the critical shortage of kidney donors, the increasing dependence on dialysis underscores the essential role of AVF devices in managing ESRD. The escalating rate of kidney disease is also driving the demand for more advanced and innovative AVF solutions. AV fistulas are preferred for long-term vascular access because of their durability, lower infection rates, and reduced complication risk compared to other access types. These factors are propelling the growth of AVF devices in the U.S.
Two other types of vascular access for hemodialysis, arteriovenous graft (AVG) and central venous catheter (CVC), are the primary substitutes for an arteriovenous fistula. The choice of access has significant clinical and economic implications, directly impacting market dynamics. While AVFs are considered the gold standard due to lower infection rates and better longevity, their long maturation time and high primary failure rate make substitutes necessary.
U.S. Arteriovenous Fistula Devices Market Report Segmentation
This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. arteriovenous fistula devices market report based on type and end-use.Type Outlook (Revenue, USD Million, 2021-2033)
- AVF Creation Devices
- AVF Monitoring Devices
- AVF Maintenance Devices
End-use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Ambulatory Surgical Centers
- Dialysis Centers
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Arteriovenous Fistula Devices Market Variable Trends & Scope
Chapter 4. U.S. Arteriovenous Fistula Devices Market: Type Estimates & Trend Analysis
Chapter 5. U.S. Arteriovenous Fistula Devices Market: by End Use Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this U.S. Arteriovenous Fistula Devices market report include:- edtronic
- D
- eleflex Incorporated
- resenius Medical Care
- . Braun Medical Inc.
- olymed
- aminate Medical Technologies Ltd.
- ook Group
- miths Group plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | September 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 112 Million |
| Forecasted Market Value ( USD | $ 120 Million |
| Compound Annual Growth Rate | 0.9% |
| Regions Covered | United States |
| No. of Companies Mentioned | 9 |
